Correlation Between Phathom Pharmaceuticals and Trevi Therapeutics
Can any of the company-specific risk be diversified away by investing in both Phathom Pharmaceuticals and Trevi Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Phathom Pharmaceuticals and Trevi Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Phathom Pharmaceuticals and Trevi Therapeutics, you can compare the effects of market volatilities on Phathom Pharmaceuticals and Trevi Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Phathom Pharmaceuticals with a short position of Trevi Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Phathom Pharmaceuticals and Trevi Therapeutics.
Diversification Opportunities for Phathom Pharmaceuticals and Trevi Therapeutics
0.63 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Phathom and Trevi is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding Phathom Pharmaceuticals and Trevi Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Trevi Therapeutics and Phathom Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Phathom Pharmaceuticals are associated (or correlated) with Trevi Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Trevi Therapeutics has no effect on the direction of Phathom Pharmaceuticals i.e., Phathom Pharmaceuticals and Trevi Therapeutics go up and down completely randomly.
Pair Corralation between Phathom Pharmaceuticals and Trevi Therapeutics
Given the investment horizon of 90 days Phathom Pharmaceuticals is expected to under-perform the Trevi Therapeutics. In addition to that, Phathom Pharmaceuticals is 2.22 times more volatile than Trevi Therapeutics. It trades about -0.31 of its total potential returns per unit of risk. Trevi Therapeutics is currently generating about -0.1 per unit of volatility. If you would invest 318.00 in Trevi Therapeutics on August 29, 2024 and sell it today you would lose (30.00) from holding Trevi Therapeutics or give up 9.43% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Phathom Pharmaceuticals vs. Trevi Therapeutics
Performance |
| Timeline |
| Phathom Pharmaceuticals |
| Trevi Therapeutics |
Phathom Pharmaceuticals and Trevi Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Phathom Pharmaceuticals and Trevi Therapeutics
The main advantage of trading using opposite Phathom Pharmaceuticals and Trevi Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Phathom Pharmaceuticals position performs unexpectedly, Trevi Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Trevi Therapeutics will offset losses from the drop in Trevi Therapeutics' long position.The idea behind Phathom Pharmaceuticals and Trevi Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
| Trevi Therapeutics vs. Cue Biopharma | Trevi Therapeutics vs. AN2 Therapeutics | Trevi Therapeutics vs. Bioatla | Trevi Therapeutics vs. Spero Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Complementary Tools
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |